about
The burden of liver disease in Europe: a review of available epidemiological data.Microbial dysbiosis in colorectal cancer (CRC) patientsRomiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopeniaEfficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia.Antiplatelet antibodies detected by the MAIPA assay in newly diagnosed immune thrombocytopenia are associated with chronic outcome and higher risk of bleeding.Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.Glutathione deficiency in cardiac patients is related to the functional status and structural cardiac abnormalities.Long-term complications of splenectomy in adult immune thrombocytopenia.Expertise of French laboratories in detection, genotyping, and quantification of hepatitis C virus RNA in serumRole of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patientsRelationship between ventilatory settings and barotrauma in the acute respiratory distress syndrome.Pulmonary hypertension and cor pulmonale during severe acute chest syndrome in sickle cell disease.Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study.Revision total hip arthroplasty performed after fracture of a ceramic femoral head. A multicenter survivorship study.Treatment of spinal epidural compression due to hematological malignancies: a single institution's retrospective experienceColon ischemia following abdominal aortic aneurysm repair in the era of endovascular abdominal aortic repair.Score Predicting Acute Chest Syndrome During Vaso-occlusive Crises in Adult Sickle-cell Disease PatientsSofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.Integration of MRI to clinical nomogram for predicting pathological stage before radical prostatectomy.A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults.2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV.Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients.Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.Factors associated with postoperative complications in elderly patients with skin cancer: A retrospective study of 241 patients.Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment Monitoring.Performance of rapid diagnostic tests for the detection of anti-HBs in various patient populations.Type II endoleaks after endovascular repair of abdominal aortic aneurysm are not always a benign condition.High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients.Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France.Past excessive alcohol consumption: a major determinant of severe liver disease among newly referred hepatitis C virus infected patients in hepatology reference centers, France, 2001.Serological viral testing of cadaveric cornea donors.Impact of hepatitis C triple therapy availability upon the number of patients to be treated and associated costs in France: a model-based analysis.Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.HEPACOM: multicenter, observational prospective study of outcome and monitoring of HCV positive antiviral-naïve patients managed in the French health care system.Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia.
P50
Q30590517-3BD40EA9-987A-49C9-BC03-DA8C0278D28FQ30997982-BFA7C488-C064-450E-9006-02780426BA4BQ33396652-69840FEB-262E-41AC-A25A-B96557B998FCQ33406127-10DEF3A9-6D0B-4281-90FB-A58320A00E57Q33408621-B468AF99-7B26-49F2-9E37-A0E992C2BDADQ33409515-7053B77B-DDC0-42B1-9347-782D1DD02233Q33411608-D3878530-BC36-4D24-A2E7-C7C7362DE96CQ33414573-3FE96CC7-0646-4A8A-A900-1617BCF45CA7Q33418033-EA3190BE-B1A6-4B7F-B18A-3E31A47E0FFBQ33421711-D3FCD71F-E8AA-4819-BF5F-4BA65D1F1C3DQ33437227-4224AD1A-8B5A-4877-87F2-A2AD764F371EQ33712557-D192CBF3-3BDC-49A5-A2DF-A61731383CEAQ33866483-D26A06A1-6B69-4890-BA6C-7BFC15142212Q34609957-85D3CC02-95EB-4C64-8F7C-C70E5380D3C1Q34733041-DFD2C9D8-9B9B-46AB-AAD5-016A239EAE8CQ35073559-46DA255F-AF44-427B-A43F-9A0F182CB7CFQ35120073-8C4E09B5-6F86-40D9-A6DE-0F0FF1F4A00BQ36648562-0DE931EB-7FA3-4FA6-BE2F-452E0F2BE68EQ37074412-1560E797-8954-4E31-9FD8-BB6AD18EE251Q37221488-A2361E1C-7AB5-438E-BBA5-4F21839329F8Q38860200-1A39C1F8-7F5E-45DC-B6C2-65F13A3C8EB9Q39085006-D9CFAFC9-5CBF-4B05-977A-10F8BDDF2D70Q39299164-5F670761-7614-42A0-A320-DDBC4EC89314Q39864556-01FACCE1-4973-45C7-9DEE-FB7EFED895E6Q40363938-9EFB0FB9-7988-4BE7-A972-A26400FC02D0Q40801524-0C1B0E07-C204-484E-A526-A2F1FE7066D1Q40832565-42EF7761-627F-4A81-A7CF-BA7BB1F12A66Q40933469-F3364E76-62E7-4EEE-8871-F5EE407F9197Q41019184-41D9BD5A-5F66-466F-B880-48EF1E50D0D2Q41923549-F5165B32-C8B3-4633-B4D4-C8DC1CB8DACFQ42690390-E0A48ABB-9487-4683-9428-E005BCB89BBBQ42851862-EC606CA9-78D6-46CB-A2D0-4F476EB312BEQ42912598-40A289E0-63BD-4DD2-B4F7-560C448A913FQ42994668-B84FC6C3-70B9-4ED0-8A81-874050F0B566Q43031817-F18CF7B4-9570-4599-B24F-250C9D5CBFAEQ43040652-902BA177-1ECA-4A8C-92E4-DC6E2A81D4C2Q43047280-B6AF02AD-DFFB-4BA9-8604-996595EEC088Q43476058-14C073DD-B418-4806-A8E2-6A813216540FQ43672646-788C69EB-F39A-4FAA-BE6A-071B2C010792Q43889358-80009488-6361-4521-9DB2-B13AC027ED0F
P50
name
Françoise Roudot-Thoraval
@ast
Françoise Roudot-Thoraval
@en
Françoise Roudot-Thoraval
@fr
Françoise Roudot-Thoraval
@nl
type
label
Françoise Roudot-Thoraval
@ast
Françoise Roudot-Thoraval
@en
Françoise Roudot-Thoraval
@fr
Françoise Roudot-Thoraval
@nl
prefLabel
Françoise Roudot-Thoraval
@ast
Françoise Roudot-Thoraval
@en
Françoise Roudot-Thoraval
@fr
Françoise Roudot-Thoraval
@nl